Abstract
ConclusionsThe antihistamine chlorpheniramine maleate is effective in preventing ETI, postirradiation performance decrement, and in reducing the hypotension observed in monkeys after a 4000-rad dose of mixed gamma-neutron radiation. Since the major pharmacological effect of chlorpheniramine is blocking histamine receptor sites, its effectiveness in preventing or modifying the radiation-induced performance changes and hypotension can be taken as further evidence that histamine is involved in acute radiation syndrome. However, the ETI-ameliorating properties of chlorpheniramine are not mediated through the maintenance of arterial blood pressure. An earlier study (9) in which similarity trained and irradiated monkeys were infused with norepinephrine so that blood pressure was maintained above 100 mm Hg did not show significant differences in performance from controls. Some mechanism other than deficient blood pressure, yet capable of being ameliorated by chlorpheniramine, is implicated in ETI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
